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Background: Visceral leishmaniosis is a potentially life-threatening illness caused by a protozoan parasite of the
genus Leishmania. It is found mainly in areas where both the parasite and its vector are endemic and is one of the
most challenging infectious diseases in the world to control. HIV infected patients are vulnerable to Leishmania
infections, and the main reservoir hosts of Leishmania infantum parasites are domestic dogs. Here, we evaluated
the long-term efficacy of treatment with meglumine antimoniate plus allopurinol (G1) compared to miltefosine
plus allopurinol (G2) in dogs naturally infected L. infantum.
Methods: Eighteen dogs with leishmaniosis were divided into the following two groups: G1 (n = 9) was treated
subcutaneously with meglumine antimoniate (100 mg/kg/day/30 days) plus allopurinol (10 mg/kg/per day/30 days),
while G2 (n = 9) was treated orally with miltefosine (2 mg/Kg/day/30 days) plus allopurinol (10 mg/kg/day/30 days).
Thereafter, the same dose of allopurinol was administered to both groups for 6 years. Leishmania DNA in lymph
node aspirates from the G1 and G2 dogs was quantified by real-time quantitative PCR at baseline and every
3 months for 24 months, and then at 28, 36, 48, 60 and 72 months. At each assessment, the dogs were examined
for signs of disease, and their clinical scores were recorded.
Results: Both combination therapies produced significant clinical improvements in the dogs, with a significant
reduction in the parasitic load in the lymph nodes of the dogs from both groups after 3 months of
treatment. Clinical relapses were observed in four dogs from G2 (miltefosine/allopurinol), and just one dog
from G1 (meglumine antimoniate/allopurinol). All dogs that relapsed had increased clinical scores, and
increased anti-Leishmania antibody titers and parasitic loads in their lymph nodes.
Conclusions: Long-term, the clinical and laboratory findings of the G1 dogs were more stable than those of
the G2 dogs, thus indicating that meglumine antimoniate had better clinical efficacy than miltefosine. The
results suggest that treatment with allopurinol as a maintenance therapy is crucial for stabilizing the care of
canine leishmaniosis.
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Leishmaniosis is a protozoan infection of dogs, and Leish-
mania infantum (syn. L. chagasi) is the most important
etiological agent [1].
Several drugs used to treat the disease are able to tem-
porarily improve the clinical signs or clinically cure dogs,
but none of these treatments reliably eliminates the infec-
tion. The most commonly used treatments for CanL are a
combination of meglumine antimoniate plus allopurinol,
or miltefosine plus allopurinol. Some studies have shown
that these drugs, alone or in combination, can clinically
cure most dogs of the disease, but they do not lead to
complete elimination of the parasite [2–4].
Miltefosine, a phospholipid (hexadecyl-phosphocholine)
originally developed as an oral antineoplastic agent, has
been registered in India for the treatment of human vis-
ceral leishmaniosis since March 2002 [5]. It is the first and
still remains the only oral drug that can be used to treat
leishmaniosis [6]. The drug was chosen for the elimination
of leishmaniosis in India, Nepal and Bangladesh because
of its ease of application in parasite control programs [7].
However, recent studies have shown that its efficacy ap-
pears to have declined because its relapse rate has doubled
[8]. Additionally, our previous study showed that treat-
ment with miltefosine alone reduced Leishmania replica-
tion but the parasite was not completely removed from
the lymph nodes. For this reason, the action of miltefosine
for the treatment of canine leishmaniosis appears to be in-
effective [9].
In most parts of the world, the most widely used treat-
ment for human and canine leishmaniosis is meglumine
antimoniate [10]. Meglumine antimoniate, which has a par-
asiticidal activity and also potentiates the phagocytic cap-
acity of macrophages [11], causes a marked decrease in the
parasite load in dogs during the first four weeks of treat-
ment [3–12]. In contrast, allopurinol has a parasitostatic
activity and long-term administration keeps the parasite
load low thereby preventing relapses [13, 14]. Previous
studies have shown that in combination, miltefosine and
allopurinol have similar efficacy as the ‘’gold standard”
treatment with meglumine antimoniate and allopurinol;
however, the follow-up period for these studies was less
than seven months [15].
In the present study, to evaluate the efficacy of the two
treatments, meglumine antimoniate plus allopurinol ver-
sus miltefosine plus allopurinol, we monitored 18 dogs
with leishmaniosis for 6 years to determine if the disease
could be eradicated in them.
Methods
Ethical statement
Dogs with leishmaniosis were treated and monitored ac-
cording to the guidelines for the control of canine leish-
maniosis issued by the Regione Campania, which providescompulsory medical treatment for dogs and the periodic
monitoring of dogs in this part of Southern Italy. All dogs
in this study were infected with leishmaniosis and were,
therefore, treated according to the regional legislation and
the involvement of the Animal Welfare Committee. Writ-
ten consent from all dog owners was obtained to allow us
to perform clinical evaluations of the dogs, as well as col-
lecting blood and lymph node aspirate samples at the time
of diagnosis and during the post-therapy follow-up. All
the procedures were performed in the presence of the dog
owners and good veterinary practice was used to avoid
suffering in the dogs. Also, in this retrospective study no
dogs were sacrificed.
Inclusion criteria
The trial was performed using 18 dogs with leishmaniosis
hospitalized at the Department of Veterinary Medicine and
Animal Productions of the University of Naples Federico II
(Naples, Italy). All the dogs were enrolled between May
2001 and January 2013 and were followed-up for at least
6 years. The diagnosis of leishmaniosis in the dogs was
based on the clinical manifestations, a positive immuno-
fluorescence test (IFAT) the presence of anti-Leishmania
serum antibodies, and a positive real-time quantitative
PCR assay (RTQ-PCR) to determine the presence of the
parasite and estimate its DNA load.
Exclusion criteria
Dogs with renal failure or with a concomitant disease that
might interfere with evaluation of treatment responses were
excluded. Additionally, ehrlichiosis was ruled out by a spe-
cific Ehrlichia canis IFAT, and by clinical examination and
hematological tests (thrombocytopenia and leukocytosis).
Dogs previously treated with leishmanicidal or leishmanio-
static drugs before inclusion were also excluded.
Visit schedule and sample collection
Before therapy, all the dogs enrolled in the study showed
clinical signs and clinic-pathological abnormalities char-
acteristic of CanL at the time of diagnosis. Post-therapy
assessments were performed on day 30 and thereafter at
3, 6, 9, 12, 15, 18, 21, 24, 28, 36, 48, 60, and 72 months.
Before therapy and during the post-therapy follow-up,
and with the consent of the dog owners, blood and
lymph node aspirate samples were collected from the
dogs. Clinical evaluation of the dogs and their hemato-
biochemical profiles (including blood cell counts; aspar-
tate transaminase, AST; alanine aminotransferase, ALT;
total serum proteins, creatinine, urea, albumin/globulin
ratio, urine analysis, and IFAT) were recorded. Dogs
were scored based on the presence and severity of signs
attributable to CanL (i.e., weight loss, dermatitis, skin ul-
cers, alopecia, ocular lesions, generalized lymphadeno-
megaly, splenomegaly, epistaxis, hemorrhagic diarrhea,
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lesions, and liver involvement), the laboratory parameters,
and the sum of the values were recorded to give a clinical
score as described previously [9]. In addition, imaging
techniques, such as radiography and/or echography, were
appropriately performed in all cases in which other con-
comitant causes were suspected. The dogs were also clas-
sified following the clinical guide lines proposed by Solano
Gallego et al. [16].
Treatment
With the agreement of their owners, the study dogs were
allocated to two treatment groups. The orally adminis-
tered drug treatment was preferable where there was a
risk of a dog bite, while the parenteral drug treatment
was preferred in dogs which were not controlled during
the early stages of administration to avoid the possibility
that nausea caused expulsion of the drug via regurgita-
tion or vomiting.
The two treatment groups were as follows: Group 1
(G1) contained nine dogs with leishmaniosis treated with
meglumine antimoniate (100 mg/kg/per day/30 days,
subcutaneous) plus allopurinol (10 mg/kg/per day/sine
die; per os, PO); Group 2 (G2) contained nine dogs with
leishmaniosis treated with miltefosine (2 mg/Kg/per day/
30 days, PO) plus allopurinol (10 mg/kg/per day/sine
die, PO). After 30 days of combined therapy, allopurinol
was continued at the same dose until the end of the
study period (6 years). Thus, the dogs received allopur-
inol for the entire 72-month study period. G1 and G2
each contained one dog where itching was observed as a
side-effect. In both cases we decided to discontinue the
treatment for 1 month before recommencing allopurinol
administration. Relapsing dogs were re-treated with
meglumine antimoniate/miltefosine in combination with
allopurinol for another 30 days.
Efficacy of treatment: clinical outcome and laboratory
analyses
With the consent of the dog owners, the efficacy of each
therapy was evaluated at each time-point based on the
clinical and laboratory responses to treatment of each
dog.
Efficacy of treatment: parasite burden
At each time point, the Leishmania DNA load in the
lymph node aspirates was determined by RTQ-PCR ana-
lysis of the parasite DNA using a method described pre-
viously [3].
Statistical methods
All data are reported as the average, standard deviation
(SD), and standard error (SE). Statistical analyses of the data
were performed using a Student's t-test and an analysis ofvariance (ANOVA); p values less than 0.05 were considered
statistically significant.
Results
The clinical scores and serological data for the two popu-
lations in each treatment group were recorded over time.
We also recorded changes in the parasitic load in the
lymph nodes before and after therapy.
Clinical outcomes and laboratory analyses
Clinical examination of both study groups was carried
out before therapy and at all times during the follow-up
as indicated in the Material and Methods section. The
clinical scores, IFAT results, and the Leishmania DNA
load recorded in this study are shown in Tables 1, 2,
and 3, respectively. The clinical score for each dog (ob-
tained following the guide lines proposed by Solano
Gallego [16] is shown in Additional file 1: Table S1,
in which the basal state clinical evaluation was compared
with that obtained by the Poot method [17], as was
performed herein. The hemato-biochemical alterations
observed most frequently included moderate anemia,
thrombocytopenia, leukopenia, increased β-γ globulins,
and hepatic enzymes.
Table 1 shows the pre-therapy scores for the clinical
basal state of both groups of dogs based on the presence
and severity of the clinical signs and laboratory parameters.
The scores for both groups were comparable and not sta-
tistically different (6.2 vs 6.0 as averages), while the inter-
individual variability (standard deviation) of the groups
was 1.6 for G1 and 1.7 for G2. The results of the ANOVA
(with Bonferroni post-hoc test) among all scores showed
that the basal state was significantly higher than all of
the other time points (from 1 to 72 months) in both treat-
ment groups. After thirty days of therapy with meglumine
antimoniate or miltefosine, an improvement in the clinical
condition of both groups was observed, even though the
scores were significantly reduced in G1 dogs where the
score decreased an average of 4.5 points (from 6.2 to 1.7)
compared to the G2 dogs where the score reduced by
2.3 points (from 6.0 to 3.7). Conversely, the G2 clinical
score by ANOVA one month after therapy was signifi-
cantly higher than all the other time points (from 3 to
72 months). In this analysis, just one comparison was not
statistically significant (1 month vs 6 months) and this was
related to a relapse in two of the dogs. In G1 a dog re-
lapsed after 12 months while the other subjects were
asymptomatic. In contrast, there were no observable re-
lapses in the G2 dogs after 12 months, and there was an
improvement in their symptoms compared to the previous
months; however, only six out of nine dogs were clinically
cured. From month 15, all the G1 dogs were clinically
cured. Contrastingly, two G2 dogs relapsed at 28 and
48 months. Hence, a second 30-day cycle of the drug,
Table 2 IFAT score changes in G1 and G2 treated dogs during
follow-up post-therapy. Data are reported as mean and (SD)
Time course G1 G2 p*
months n = 9 n = 9
Basal 2.8 3.3 0.1093
(1.1) (0.7)
1 1.3 3.3 0.0001
(0.9) (0.7)
3 2.6 2.3 0.2818
(0.5) (1.0)
6 1.6 3.2 0.0004
(0.7) (1.0)
9 0.9 1.2 0.1408
(0.3) (0.8)
12 1.1 1.0 0.4050
(1.2) (0.7)
15 1.0 1.2 0.2177
(0.5) (0.7)
18 1.0 0.9 0.2934
(0.0) (0.6)
21 0.9 1.0 0.3377
(0.6) (0.5)
24 0.9 1.3 0.0537
(0.6) (0.5)
28 1.0 1.6 0.1550
(0.7) (1.4)
36 1.0 1.4 0.1277
(0.9) (0.7)
48 1.0 1.6 0.0982
(0.5) (1.1)
60 1.0 1.2 0.1661
(0.0) (0.7)
72 0.3 0.8 0.0646
(0.5) (0.7)
*Student’s t-test probability significance between groups
Table 1 Clinical score changes in G1 and G2 treated dogs during
follow-up post-therapy. Data are reported as mean and (SD)
Time course G1 G2 p*
months n = 9 n = 9
Basal 6.2 6.0 0.3894
(1.6) (1.7)
1 1.7 3.7 0.0051
(1.7) (1.2)
3 1.3 1.7 0.1922
(1.0) (0.5)
6 0.6 2.3 0.0246
(0.7) (2.4)
9 0.0 1.0 0.0380
(0.0) (1.6)
12 0.9 0.4 0.3180
(2.7) (0.7)
15 0.2 0.1 0.3304
(0.7) (0.3)
18 0.1 0.3 0.1418
(0.3) (0.5)
21 0.1 0.3 0.1418
(0.3) (0.5)
24 0.2 0.3 0.3119
(0.4) (0.5)
28 0.3 0.9 0.0862
(0.7) (0.9)
36 0.0 0.4 0.0111
(0.0) (0.5)
48 0.0 0.8 0.0243
(0.0) (1.1)
60 0.0 0.4 0.0750
(0.0) (0.9)
72 0.0 0.4 0.0426
(0.0) (0.7)
*Student’s t-test probability significance between groups
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lapsed subjects in the G1 (n = 1) and G2 (n = 4) groups,
respectively.
The IFAT scores in Table 2 show that in both groups
the anti-Leishmania antibody titers in the blood de-
creased progressively from 2.8 (basal) to 0.3 (72 months)
in G1 and from 3.3 to 0.8 in G2. However, the anti-
Leishmania antibody levels in G1 were consistently
lower than G2 as early as 6 months during the follow-up
period. In G2, however, we observed a rise in the anti-
body titers in conjunction with the clinical relapses. A
comparison of the clinical and IFAT scores is shown inFig. 1. The total score obtained from the sum of the clin-
ical and IFAT values is also shown in Fig. 1, panel a.
The IFAT score for the basal state was significantly
higher than all the other time points (from 1 to 72 months)
in G1 and just one comparison was not significant (basal
vs 3 months). The G2 IFAT score for the basal state was
significantly higher than all the other time points (from
9 to 72 months); however, the basal score was not signifi-
cantly different for the 1, 3 and 6 months post-therapy
values (by ANOVA).
At 30 days post-therapy with meglumine antimoniate
or miltefosine, the IFAT value decreased by 1.5 points
Table 3 DNA load changes in G1 and G2 treated dogs during
follow-up post-therapy. Data are reported as mean and (SD)
Time course G1 G2 p*
months n = 9 n = 9
Basal 4952 5222 0.4385
(3341) (3935)
1 386 1723 0.0686
(417) (2528)
3 94 149 0.1356
(84) (120)
6 91 944 0.1255
(79) (2148)
9 76 184 0.1114
(19) (253)
12 795 88 0.1687
(2140) (153)
15 71 56 0.2475
(17) (63)
18 43 32 0.2173
(16) (36)
21 36 37 0.4520
(19) (36)
24 33 778 0.1529
(18) (2112)
28 16 1155 0.1448
(7) (3119)
36 14 256 0.1464
(5) (667)
48 4 756 0.1622
(3) (2220)
60 7 114 0.1444
(4) (292)
72 16 98 0.1616
(27) (243)
*Student’s t-test probability significance between groups
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changed (from 3.3 vs 3.3). The G2 IFATvalue after 1 month
of therapy was significantly higher (by ANOVA) than all
the other time points (from 9 to 72 months), and just two
comparisons were not significant (1 month vs 3 and
6 months).
In G1, the IFAT after 3 months was significantly higher
than all the other time points (from 9 to 72 months) and
just one comparison was not significant (3 vs 6 months).
The G2 IFAT after 3 months was not significantly higher
than all the other time points (from 6 to 72 months) and
just two comparisons were significant (3 vs 18 and72 months). In G1, the IFAT score at 6 months com-
pared to all the other scores showed just one value that
was significantly higher (6 vs 72 months). In contrast,
the IFAT scores of the G2 dogs at the 6-month evalu-
ation were significantly higher than all the other time
points (from 9 to 72 months).
The quantitative measurements of the DNA in the
lymph nodes did not differ significantly in either group
at baseline, and on average, the values of Leishmania
DNA per ml of aspirate for the G1 and G2 dogs were
4952 (range 981–9100) and 5222 (range 159–10,000), re-
spectively. Table 3 shows that the Leishmania load be-
fore therapy in both groups of dogs was not statistically
different (4952 vs 5222, average values). Inter-individual
variability between the groups (standard deviation) was
3341 in G1 and 3935 in G2 (Table 3). The score for the
basal state compared to all the other time points (from 1
to 72 months) was significantly higher in both groups of
dogs (by ANOVA). Figure 2 shows that in both groups the
Leishmania load after therapy decreased strongly, particu-
larly after 30 days of therapy. Additionally, the parasite
load decreased on average by 4565 parasites (from 4952 to
386) in G1 compared to G2 where the load was reduced
by 3500 parasites (from 5222 to 1723). The ANOVA also
showed that the Leishmania load after 1 month of therapy
in both groups of dogs did not differ significantly for all
the time points (from 3 to 72 months). The decrease in
parasite load for G1 was already statistically significant
after just one month of treatment, with a linear decrease
in the subsequent nine months reaching an average value
of 76 Leishmania per ml of aspirate (range 42–98). In
contrast, the G2 dogs showed higher variability within
their group (compared with G1), and at 9 months had an
average value of 184 Leishmania per ml of aspirate (range
35–698).
In both groups at 3 months after commencing treat-
ment, the parasite load did not differ statistically from
each other, and the decreased parasite load in G1 and G2
was about 50 and 35 times lower than the initial values,
respectively. At 12 months an increase in the Leishmania
DNA load was apparent in G1, the average value of which
was higher than in G2. In particular, there was higher vari-
ability within G1; this was caused by a relapse in one of
the dogs that had an increased DNA load (6501 L/ml of
aspirate). From months 15 to 21, the Leishmania DNA
load for both groups was stable and much lower than that
of the basal state.
From month 24, the Leishmania DNA load in the G1
and G2 dogs differed from each other. In fact, the DNA
load in G2 was consistently higher than that in G1, but
not statistically different. Additionally, G2 showed more
variability in the DNA load compared with G1. However,
in all cases the DNA loads for G1 dogs from month 24
onwards were below 33 parasites per ml of aspirate. In
Fig. 1 Clinical and laboratory scores for G1 and G2 dogs during the post-therapy follow-up period. The scores were recorded at baseline, then
every three months for 24 months, and then at 28, 36, 48, 60 and 72 months. The data for (a) total score (clinical + IFAT score), (b) clinical score,
and (c) IFAT score. Scores are reported as the average and standard deviation
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72 month period, the DNA load was below three parasites
per ml of aspirate, and only one dog had an undetectable
Leishmania load at 72 months post-treatment.
Discussion
This longitudinal study involved constant and systematic
monitoring of 18 dogs with leishmaniosis over 6 years in
order to evaluate the efficacy of two different treatments,meglumine antimoniate/allopurinol versus miltefosine/
allopurinol. It is the first comparative study of two different
drug combinations performed by evaluation of the clinical
parameters, the hemato-biochemical profiles (urea, serum
total protein, creatinine, globulins and albumin, AST, ALT),
the serological (IFAT), and molecular (RTQ-PCR) data.
Clinical improvement occurred rapidly in the G1 dogs
(30 days after meglumine antimoniate/allopurinol therapy)
and less rapidly in the G2 dogs (3 months after miltefosine/
Fig. 2 Leishmania DNA load in G1 and G2 dogs. The parasite load in the lymph node during the post-therapy follow-up was measured by
RTQ-PCR. Data are reported as the logarithms of the average values and their standard deviations
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reports [14, 18, 19], almost all the dogs in both groups were
free of clinical signs at 90 days after drug treatment.
The incidence of clinical recurrence was higher in the
G2 dogs than in the G1 dogs from 12 months after start-
ing therapy. Indeed, in G1, eight of nine dogs were clinic-
ally cured, and by month 12 only one dog had relapsed.
From month 15, all G1 dogs were clinically cured. How-
ever, in G2, two dogs relapsed at 6 months and two dogs
relapsed at 28 and 48 months. RTQ-PCR analysis of para-
site DNA in the lymph nodes of the dogs with leishmanio-
sis treated with a combination of meglumine antimoniate
and allopurinol showed there was a significant decrease in
the parasite load of the G1 dogs after only one month of
therapy, with a linear decrease observed in the subsequent
nine months. In particular, in three dogs from this group
the DNA load in their lymph nodal aspirates was below 3
Leishmania parasites per ml of aspirate from 48 months
to the end of the observation period (6 years). Further-
more, the DNA load of the parasite in one dog was un-
detectable at 72 months. These values are considered
negligible when compared to the initial values, and are in
agreement with those reported previously in infected dogs
from areas where Leishmania is endemic; dogs from en-
demic regions react to the parasite by immune response
activation, and thereby remain clinically healthy or asymp-
tomatic for long periods [20]. In contrast, G2 dogs that
received miltefosine plus allopurinol showed greater
variability within the group, and although the parasite
load in both groups was similar at 3 months, from month
24 the Leishmania DNA load showed a different trend be-
tween the two groups of dogs with the number of para-
sites in G2 being higher than that of G1 (not statistically
significant).In this study, we found a positive correlation between
the clinical score and the antibody titer (IFAT score) in
both groups of dogs (G1 and G2), with correlation factors
(r) of 0.802 and 0.877, respectively. We also found a posi-
tive correlation between the total score (clinical score +
IFAT score) and parasite load in both groups (G1 and G2)
with correlation factors (r) of 0.917 and 0.861, respectively.
Also, the IFAT score versus the parasite load showed a
positive correlation for both G1 and G2 dogs, with correl-
ation factors (r) of 0.679 and 0.705, respectively. Addition-
ally, as has been suggested by Abranches et al. (1991) [21],
there was a positive correlation between the clinical score
and parasite load in G1 and G2 dogs alike, with correl-
ation factors (r) of 0.964 and 0.915, respectively. All the
correlations were statistically significant (p < 0.05). The
supplementary data (Additional file 1: Figure S1 and S2)
shows the correlations identified for the clinical and la-
boratory parameters that were investigated in the G1 and
G2 dogs. These results are in agreement with some studies
that have indicated the existence of a close correlation be-
tween the clinical response and IFAT score reduction after
therapy [14, 22]. The results differ from other studies that
have shown that IFAT titers can be high in clinically
negative dogs [23]. Here, in both G1 and G2 groups,
excluding the findings for G1 after 72 months, all the
dogs had antibodies against Leishmania parasites, and
the IFAT scores in both groups correlated positively with
their clinical scores and parasite loads. Therefore, ser-
ology does not seem to be a reliable way to monitor
treatment efficacy in the short-term [23]. There was no
correlation between the serological titers and the severity
of the clinical signs. It is concluded that the ELISA is a
sensitive method for the diagnosis of canine leishma-
niosis but is not satisfactory for monitoring the clinical
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associated with high parasitism and disease [24]. However,
the presence of low antibody levels is not necessarily indi-
cative of the disease and further work-up is necessary to
confirm or exclude clinical leishmaniosis by other diag-
nostic methods [4].
Notably, during the 72-month follow-up period, in all
the relapsed dogs (1 dog in G1 and 3 dogs in G2) a rise
in antibody titers was observed in conjunction with the
clinical relapses. According to Reis et al. [24], our data
confirm that IFAT is suitable for identifying Leishmania-
infected dogs, irrespective of their clinical status. How-
ever, when the clinical signs are evident, the antibody
levels increase significantly [21]. Based on these results,
and on the direct correlation between parasite load and
disease severity observed here, we suggest that the RTQ-
PCR method is suitable for monitoring changes in the
parasitic load during post-therapy follow-up, and may be
an effective way to confirm accurately the presence of par-
asites in dog tissues. This study also begins to address the
question of appropriate allopurinol dose during long-term
follow-up.
Contrary to the study by Torres et al. [14], here, allo-
purinol was administered for the entire observation period
at a dose of 10 mg/kg/per day. No symptomatic dogs had
urolithiasis, as determined by use of ecographic scanning
of the uropoietic system and by urine analysis (for blood
and microscopic sediment). Based on these findings, we
suggest that a single daily administration of allopurinol
at a dose of 10 mg/kg/day may promote greater toler-
ance of this drug. Furthermore, increasing the administra-
tion period by up to 6 years should not cause significant
side effects, as was noted in the present study. In fact, only
one dog in G1 and one in G2 had itching as a side effect
due to a long allopurinol administration period, suggesting
possible hypersensitivity of the two dogs as also observed
in humans [25–27]. In both cases the treatment was dis-
continued for one month, after the allopurinol administra-
tion was started again.
Conclusions
After the 6-year follow-up in each treatment group (G1
and G2), the average clinical scores and Leishmania loads
were significantly lower than before starting therapy. The
effects of meglumine antimoniate plus allopurinol seem
better than miltefosine plus allopurinol for treating leish-
maniosis in dogs, because during the follow-up we ob-
served a decrease in the incidence of disease recurrence.
Indeed, one of nine dogs had a recurrence in the meglu-
mine antimoniate plus allopurinol group (G1), compared
to four of nine dogs that received miltefosine plus allopur-
inol (G2). Because a relatively small number of dogs were
used in this study, it would be worth repeating it with a
larger number of dogs.Additional file
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